Published in Vaccine Weekly, June 29th, 2005
This takes the total number of filings submitted by Ranbaxy to the WHO to eleven, of which, five are fixed dose combinations (FDCs). All the ARVs filed by the company to WHO are manufactured at a plant inspected and approved by the U.S. Food and Drug Administration (FDA). The contract research organizations used by Ranbaxy to carry out these bioequivalence studies are globally reputed and conduct and file their studies...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.